MRI Monitoring of Anti-Alzheimer Therapy Amyloid-Related Imaging Abnormalities: Due Diligence or Overkill?

References

1. 1.↵
   1. Cogswell PM,
   2. Barakos JA,
   3. Barkhof F, et al

   . Amyloid-related imaging abnormalities with emerging Alzheimer disease therapeutics: detection and reporting recommendations for clinical practice. AJNR Am J Neuroradiol 2022;43:E19–35 doi:10.3174/ajnr.A7586 pmid:35953274

   Abstract/FREE Full Text
2. 2.↵
   1. Sevigny J,
   2. Chiao P,
   3. Bussière T, et al

   . The antibody aducanumab reduces Aβ plaques in Alzheimer’s disease. Nature 2016;537:50–56 doi:10.1038/nature19323 pmid:27582220

   CrossRefPubMed
3. 3.↵
   1. Klein G,
   2. Delmar P,
   3. Voyle N, et al

   . Gantenerumab reduces amyloid-β plaques in patients with prodromal to moderate Alzheimer’s disease: a PET substudy interim analysis. Alzheimers Res Ther 2019;11:101 doi:10.1186/s13195-019-0559-z pmid:31831056

   CrossRefPubMed
4. 4.↵
   1. Høilund-Carlsen PF,
   2. Alavi A

   . Aducanumab (marketed as Aduhelm) approval is likely based on misinterpretation of PET imaging data. J Alzheimers Dis 2021;84:1457–60 doi:10.3233/JAD-215275 pmid:34657891

   CrossRefPubMed